Prostate Cancer | Specialty

Researcher Hopes Liquid Biopsies Will Make Mark in Prostate Cancer

November 21st 2016

How oncologists can translate their increased understanding of the biology of prostate cancer into clinical practice is a question being raised currently in the field, explains Howard I. Scher, MD, adding, that the emergence of liquid biopsies could possibly be one way to tackle the issue.

Biomarkers, Combo Regimens Key to Mitigating AR-Resistance in mCRPC

November 21st 2016

A number of clinical trials are seeking to identify beneficial therapeutic outcomes in patients with prostate cancer who are resistant to androgen receptor–targeted agents.

Dr. Robert Dreicer on Overcoming Resistance Pathways in mCRPC

November 21st 2016

Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses next-generation antiandrogen therapies in metastatic castration-resistant prostate cancer (mCRPC).

Dreicer Discusses Optimizing Treatment in mCRPC

November 19th 2016

As oncologists await the next major treatment advances in metastatic castration-resistant prostate cancer (mCRPC), the key in the interim is to optimize the available therapies, says Robert Dreicer, MD.

Dr. Stein on Circulating Biomarkers in Prostate Cancer

November 19th 2016

Mark Stein, MD, medical oncologist, Rutgers Cancer Institute of New Jersey, discusses the use of novel circulating biomarkers in the treatment of patients with prostate cancer.

Dr. Morris on Novel Approaches With Radium-223 in mCRPC

November 18th 2016

Michael J. Morris, MD, an associate professor of Medicine at Memorial Sloan Kettering Cancer, discusses what novel combinatorial approaches researchers will be explored with radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Kantoff on Evolving Role of Docetaxel in Prostate Cancer Treatment

November 18th 2016

Philip W. Kantoff, MD, chairman of Medicine at Memorial Sloan Kettering Cancer Center and a 2014 Giants of Cancer Care winner for Genitourinary Cancer, discusses the role that chemotherapy treatment with docetaxel will continue to have in patients with prostate cancer. Kantoff shared this insight in an interview during the 2016 OncLive State of the Science Summit on Genitourinary Cancers.

Dr. Scher on Predicting Sensitivity to Treatment for mCRPC

November 18th 2016

Howard I. Scher, MD, chief, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, discusses understanding the genetics of patients with metastatic castration-resistant prostate cancer.

Kantoff Highlights Continued Role for Docetaxel in Metastatic Prostate Cancer

November 16th 2016

While immunotherapy continues to make headway in various malignancies, the chemotherapy docetaxel maintains a key role in the treatment of patients with metastatic prostate cancer.

Newly Identified Molecular Subtypes Could Guide Treatment Decisions in Prostate Cancer

November 16th 2016

Researchers have identified 3 distinct molecular subtypes of primary prostate cancer that correlate with distant metastasis-free survival and response to radiation therapy.

Dr. Rathkopf on Mitigating AR-Resistance in Prostate Cancer

November 15th 2016

Dana E. Rathkopf, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses mitigating androgen receptor (AR)-resistance in patients with prostate cancer.

Dr. Bryan Mehlhaff on Advances in mCRPC

November 12th 2016

Bryan Mehlhaff, MD, medical director of research for Oregon Urology Institute, discusses recent advancements in and what he sees on the horizon for metastatic castrate-resistant prostate cancer (mCRPC).

Dr. Dreicer on Combination Trials With Radium-223 in mCRPC

November 12th 2016

Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses the potential of combination regimens involving radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Spratt on Growing Role for Genetic Testing in Prostate Cancer

November 9th 2016

Daniel Eidelberg Spratt, MD, assistant professor, radiation oncology, University of Michigan Health System, discusses genetic testing in prostate cancer.

LUGPA Will Create Bundled Payment Models for Prostate Care

November 8th 2016

The Large Urology Group Practice Association has announced the plan to create two alternative payment models that involve bundled payments.

Expert Emphasizes Impact of Robotic Surgery in Field of Prostate Cancer

November 8th 2016

David Albala, MD, discusses some of the benefits of robotic surgery and the impact it has had on the field of prostate cancer, as well as methods that larger urology groups can use to better achieve compliance.

Dr. Concepcion on the Use of Eligard in Prostate Cancer Treatment

November 7th 2016

Raoul Concepcion, MD, director, Comprehensive Prostate Center, discusses the use of Eligard in the treatment of prostate cancer with OncLive during the LUGPA Annual Meeting.

Dr. Buffington on The Use of Fusion MRI in Prostate Cancer

November 7th 2016

Philip J. Buffington, MD, Chief Medical Officer, The Urology Group, discussed the use of fusion MRI in prostate cancer with OncLive during the LUGPA Annual Meeting.

Dr. Rahul Tendulkar on Managing Side Effects of Radical Prostatectomy

November 7th 2016

Rahul Tendulkar, MD, associate staff, radiation oncology, Cleveland Clinic, discusses the side effects of a radical prostatectomy for men with prostate cancer.

Dr. David Albala on The Role of Robotic Surgery in Prostate Cancer

November 6th 2016